Showing 781-790 of 3123 results for "".
From SDPA: JAKs, Black Boxes, and What It All Means
https://practicaldermatology.com/conferences/sdpa-2024/sdpa-jaks-black-boxes-and-what-it-all-means/26286/Practitioners shouldn’t fear Janus kinase (JAK) inhibitors for their patients when appropriate, according to a wide-ranging expert chat at the 2024 SDPA Annual Summer Conference in San Diego. The conversation featured Matthew Zirwas, MD, a dermatologist with DOCS Dermatology, and Amy Spizuoco, DO, FScientifically Speaking: Applying Energy-Based Devices Across Skin Tones
https://practicaldermatology.com/series/scientifically-speaking/scientifically-speaking-applying-energy-based-devices-across-skin-tones/19895/With advancements in technology and a patient-focused approach to treatment, it's possible to safely and effectively apply energy-based devices to a range of skin concerns in patients with darker skin. Host Joel L. Cohen, MD discusses treatment strategies for melasma, acne, PFB, scarring and more wiDerm Insider: Navigating Office Politics
https://practicaldermatology.com/topics/practice-management/derm-insider-navigating-office-politics/18993/In this edition of Derm Insider, host Neal Bhatia, MD speaks with practice management experts about the complex inner workings of an office environment, as well as the role of physicians in managing precarious situations regarding employees. Offering advice for maneuvering these situations, guests SThe Case for JAK Inhibitors to Treat AD
https://practicaldermatology.com/topics/atopic-dermatitis/case-jak-inhibitors-treat-ad/27109/E. James Song, MD, FAAD, Director of Clinical Research and Co-Chief Medical Officer for Frontier Dermatology, discusses his presentation “JAK Inhibitors in Atopic Dermatitis” from the 2024 American Academy of Dermatology (AAD) Innovation Academy.Journal Club: Dupilumab and Atopic March
https://practicaldermatology.com/programs/Practical-Dermatology-Atopic-Dermatitis-Journal-Club/journal-club-dupilumab-and-atopic-march/32405/Practical Dermatology Associate Medical Editor Elizabeth (Lisa) Swanson, MD, FAAD, and Editorial Board member Peter Lio, MD, discuss recent research indicating a reduced risk of atopic march in pediatric atopic dermatitis patients on dupilumab.Lin TL, Fan YH, Fan KS, Juan CK, Chen YJ, Wu CY. ReducedWhat Every Dermatologist Must Know About the History of Black Hair
https://practicaldermatology.com/topics/hair-nails/what-every-dermatologist-must-know-about-the-history-of-black-hair/23996/Knowledge of the historical, cultural, and social significance of hairstyles of Black patients may reduce implicit bias amongst dermatologists. In this article, Brooke Jackson, MD, FAAD, and Aliya Rodriguez, BS, explore the unique history and cultral impact of black hair.Diverse by Design: The Unique Molecular Footprints of IL-23 Biologics in Psoriasis
https://practicaldermatology.com/issues/april-2024/il23_biologics_in_psoriasis/24457/Christopher Bunick, MD, PhD, discusses a study that explores the structural basis of IL-23 targeted biologic therapies for psoriasis. By mapping the binding sites of these therapies on the IL-23 molecule and correlating molecular properties with clinical efficacy, the study offers insights into whyUpdates from CSF 2017
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-updates-from-csf-2017/18371/Dermatologists and core cosmetic physicians shared new insights and reviewed the developments in clinical and cosmetic dermatology at the ninth annual Cosmetic Surgery Forum in Las Vegas. Matthew Zirwas, MD addressed interest in oral supplements to support skin health. Neurotoxin pioneer Nick Lowe,AK Burden and Progression Risk
https://practicaldermatology.com/topics/skin-cancer-photoprotection/ak-burden-and-progression-risk/20134/Individuals with chronic sun damage are at higher risk of developing AK lesions. It is therefore essential that dermatologists emphasize early sun protection recommendations and address progression risks of AK with their patients. Faced with increasing burden of skin cancers, Joel L. Cohen, MD and ADermwireTV — Bayer Buys Merck’s OTC Lines, Allergan Rejects Valeant Bid
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-mdash-bayer-buys-merck-rsquo-s-otc-lines-allergan-rejects-valeant-bid/19134/Bayer Purchases Merck's OTC Products and Allergan Rebuffs Valeant. This week DermWireTV explores Bayer's growth in the OTC space, including sunscreens, and reports new data on skin cancer mortality. Also in this edition: Neal Bhatia, MD reviews the Noah Worcester Society Annual Meeting.